Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection.

Williams N, Bossert N, Chen Y, Jaanimägi U, Markatou M, Talal AH.

J Subst Abuse Treat. 2019 Jul;102:33-39. doi: 10.1016/j.jsat.2019.04.009. Epub 2019 May 2.

PMID:
31202286
2.

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.

Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F.

J Viral Hepat. 2019 Aug;26(8):951-960. doi: 10.1111/jvh.13110. Epub 2019 May 20.

3.

Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone.

Talal AH, Andrews P, Mcleod A, Chen Y, Sylvester C, Markatou M, Brown LS.

Clin Infect Dis. 2019 Jul 2;69(2):323-331. doi: 10.1093/cid/ciy899.

PMID:
30329042
4.

Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.

Talal AH, McLeod A, Andrews P, Nieves-McGrath H, Chen Y, Reynolds A, Sylvester C, Dickerson SS, Markatou M, Brown LS.

Telemed J E Health. 2019 Sep;25(9):791-801. doi: 10.1089/tmj.2018.0161. Epub 2018 Oct 16.

PMID:
30325701
5.

Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians.

Samuel ST, Martinez AD, Chen Y, Markatou M, Talal AH.

World J Hepatol. 2018 Feb 27;10(2):319-328. doi: 10.4254/wjh.v10.i2.319.

6.

Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders.

Perumalswami PV, Talal AH.

J Infect Dis. 2018 Mar 13;217(7):1020-1023. doi: 10.1093/infdis/jix682. No abstract available.

PMID:
29294033
7.

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C.

J Infect Dis. 2018 Jan 17;217(3):474-482. doi: 10.1093/infdis/jix495.

8.

Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Gonzalez SA, Fierer DS, Talal AH.

Addict Disord Their Treat. 2017 Jun;16(2 Suppl 1):S1-S23. doi: 10.1097/ADT.0000000000000104. Epub 2017 May 17.

9.

Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders.

Talal AH, Chen Y, Zeremski M, Zavala R, Sylvester C, Kuhns M, Brown LS, Markatou M, Cloherty GA.

J Subst Abuse Treat. 2017 Jul;78:37-42. doi: 10.1016/j.jsat.2017.04.011. Epub 2017 Apr 20.

PMID:
28554601
10.

Toward Optimal Control of Hepatitis C Virus Infection in Persons With Substance Use Disorders.

Talal AH, Thomas DL, Reynolds JL, Khalsa JH.

Ann Intern Med. 2017 Jun 20;166(12):897-898. doi: 10.7326/M16-2887. Epub 2017 Apr 25. No abstract available.

PMID:
28437796
11.

Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.

Ocque AJ, Hagler CE, DiFrancesco R, Morse GD, Talal AH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:103-109. doi: 10.1016/j.jchromb.2017.03.020. Epub 2017 Mar 24.

12.

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.

Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02283-16. doi: 10.1128/AAC.02283-16. Print 2017 May.

13.

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Talal AH, Venuto CS, Younis I.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):206-212. doi: 10.1002/cpdd.336. Review.

14.

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Venuto CS, Talal AH.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):169-175. doi: 10.1002/cpdd.311.

15.

Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction.

Khalsa JH, Talal AH, Morse G.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):108-117. doi: 10.1002/cpdd.316.

PMID:
28263456
16.

Response to Commentary on Zeremski et al. (2016): Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention.

Zeremski M, Sylvester C, Talal AH.

J Addict Med. 2016 Sep-Oct;10(5):364-5. doi: 10.1097/ADM.0000000000000240. No abstract available.

PMID:
27685683
17.

Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage.

Juluru K, Talal AH, Yantiss RK, Spincemaille P, Weidman EK, Giambrone AE, Jalili S, Sourbron SP, Dyke JP.

J Magn Reson Imaging. 2017 Apr;45(4):1177-1185. doi: 10.1002/jmri.25431. Epub 2016 Aug 16.

18.

Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.

Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH.

J Infect Dis. 2016 Oct 15;214(8):1164-70. doi: 10.1093/infdis/jiw332. Epub 2016 Aug 2.

19.

Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver.

Ocque AJ, Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH.

Bioanalysis. 2016 Jul;8(13):1353-63. doi: 10.4155/bio-2016-0040. Epub 2016 Jun 9.

20.

Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention.

Zeremski M, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, Brown LS Jr, Talal AH.

J Addict Med. 2016 Mar-Apr;10(2):104-9. doi: 10.1097/ADM.0000000000000196.

PMID:
26881485
21.

IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.

Sehgal M, Zeremski M, Talal AH, Ginwala R, Elrod E, Grakoui A, Li QG, Philip R, Khan ZK, Jain P.

J Interferon Cytokine Res. 2015 Sep;35(9):698-709. doi: 10.1089/jir.2014.0211. Epub 2015 Jun 19.

22.

Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.

Wright DH, Caro L, Cerra M, Panorchan P, Du L, Anderson M, Potthoff A, Nachbar RB, Wagner J, Manns MP, Talal AH.

Antivir Ther. 2015;20(8):843-8. doi: 10.3851/IMP2958. Epub 2015 Apr 7.

23.

Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.

Sehgal M, Zeremski M, Talal AH, Khan ZK, Capocasale R, Philip R, Jain P.

J Clin Cell Immunol. 2014 Oct 31;5. pii: 1000271.

24.

Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Zeremski M, Dimova RB, Benjamin S, Penney MS, Botfield MC, Talal AH.

J Infect Dis. 2015 Jun 1;211(11):1795-9. doi: 10.1093/infdis/jiu807. Epub 2014 Dec 15.

25.

Impact of common risk factors of fibrosis progression in chronic hepatitis C.

Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F.

Gut. 2015 Oct;64(10):1605-15. doi: 10.1136/gutjnl-2014-306997. Epub 2014 Sep 11.

PMID:
25214320
26.

FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH.

BMC Gastroenterol. 2014 Jul 3;14:118. doi: 10.1186/1471-230X-14-118.

27.

Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell JE, Talal AH.

J Addict Med. 2014 Jul-Aug;8(4):249-57. doi: 10.1097/ADM.0000000000000041.

28.

Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Jacobson IM, Kwong AD.

Hepatology. 2014 Dec;60(6):1826-37. doi: 10.1002/hep.27202. Epub 2014 Jul 31.

29.

Gene expression analysis in serial liver fine needle aspirates.

Lejnine S, Marton MJ, Wang IM, Howell BJ, Webber AL, Maxwell JW, Shire N, Malkov V, Lunceford J, Zeremski M, Sun A, Ruddy M, Talal AH.

J Viral Hepat. 2015 Jan;22(1):64-76. doi: 10.1111/jvh.12213. Epub 2014 Jan 29.

30.

Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.

Zeremski M, Martinez AD, Talal AH.

Clin Infect Dis. 2014 Mar;58(6):880-2. doi: 10.1093/cid/cit804. Epub 2013 Dec 13. No abstract available.

PMID:
24336913
31.

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.

32.

Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI.

PLoS One. 2013 Nov 21;8(11):e80078. doi: 10.1371/journal.pone.0080078. eCollection 2013.

33.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants.

J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173. Review.

34.

Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C--authors' reply.

Talal AH, Lafleur J, Hoop RS, Pandya P, Martin P, Jacobson IM, Han J, Korner EJ.

Aliment Pharmacol Ther. 2013 Sep;38(5):554-5. doi: 10.1111/apt.12424. No abstract available.

35.

Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection.

Tavakkoli M, Ferrando SJ, Rabkin J, Marks K, Talal AH.

Psychosomatics. 2013 Sep-Oct;54(5):466-71. doi: 10.1016/j.psym.2013.02.009. Epub 2013 Jun 4.

PMID:
23756122
36.

Cost-effectiveness of screening for chronic hepatitis C infection in the United States.

Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE.

Clin Infect Dis. 2013 May;56(10):1382-93. doi: 10.1093/cid/cit069. Epub 2013 Feb 7.

PMID:
23392392
37.

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.

Talal AH, LaFleur J, Hoop R, Pandya P, Martin P, Jacobson I, Han J, Korner EJ.

Aliment Pharmacol Ther. 2013 Feb;37(4):473-81. doi: 10.1111/apt.12200. Epub 2013 Jan 7.

38.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
39.

Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?

Sehgal M, Khan ZK, Talal AH, Jain P.

Virology (Auckl). 2013 Feb 11;4:1-25. doi: 10.4137/VRT.S11046. eCollection 2013. Review.

40.

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH.

Clin Infect Dis. 2013 Mar;56(6):806-16. doi: 10.1093/cid/cis1007. Epub 2012 Dec 7. Review.

41.

Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients.

Boukli NM, Shetty V, Cubano L, Ricaurte M, Coelho-Dos-Reis J, Nickens Z, Shah P, Talal AH, Philip R, Jain P.

Clin Proteomics. 2012 Sep 7;9(1):11. doi: 10.1186/1559-0275-9-11.

42.

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchot C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group.

Gastroenterology. 2012 Nov;143(5):1244-1252.e12. doi: 10.1053/j.gastro.2012.07.097. Epub 2012 Jul 27.

43.

Hepatitis C virus-specific immune responses in noninjecting drug users.

Zeremski M, Makeyeva J, Arasteh K, Des Jarlais DC, Talal AH.

J Viral Hepat. 2012 Aug;19(8):554-9. doi: 10.1111/j.1365-2893.2011.01573.x. Epub 2012 Feb 22.

44.

Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Talal AH, Dimova RB, Seewald R, Peterson RH, Zeremski M, Perlman DC, Des Jarlais DC.

J Subst Abuse Treat. 2013 Jan;44(1):115-9. doi: 10.1016/j.jsat.2012.01.010. Epub 2012 Mar 8.

45.

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):261-8. doi: 10.1097/QAI.0b013e3182324af9.

46.

CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.

Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH.

J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.

47.

Hepatitis C virus infection in USA: an estimate of true prevalence.

Chak E, Talal AH, Sherman KE, Schiff ER, Saab S.

Liver Int. 2011 Sep;31(8):1090-101. doi: 10.1111/j.1478-3231.2011.02494.x. Epub 2011 Mar 16. Review.

PMID:
21745274
48.

Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, Jacobson IM, Rice CM, Dustin LB.

Blood. 2011 May 19;117(20):5425-37. doi: 10.1182/blood-2010-10-312942. Epub 2011 Mar 18.

49.

Quality of care in patients with chronic hepatitis C virus infection.

Talal AH, Perlman DC, Des Jarlais DC.

Ann Intern Med. 2011 Feb 1;154(3):213-4; author reply 214-5. doi: 10.7326/0003-4819-154-3-201102010-00018. No abstract available.

PMID:
21282706
50.

Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.

Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH.

J Hepatol. 2011 Sep;55(3):545-553. doi: 10.1016/j.jhep.2010.12.033. Epub 2011 Jan 21.

Supplemental Content

Loading ...
Support Center